Navitoclax (ABT-263)
目录号:S1001 Purity: 99.99%
Navitoclax (ABT-263)是一种有效的Bcl-xL,Bcl-2和Bcl-w抑制剂,无细胞试验中Ki分别为≤0.5 nM,≤1 nM和≤1 nM,但与Mcl-1和A1结合微弱。Phase 2。
CAS: 923564-51-6
客户使用Selleck的Navitoclax (ABT-263)发表文献367篇
- Gastroenterology, 2024 S0016-5085(24)00062-3
- Cancer Cell, 2023 41(8):1480-1497.e9
- Cell, 2021 184(25):6119-6137.e26
- Cancer Cell, 2021 S1535-6108(21)00492-X
- Cancer Cell, 2021 S1535-6108(21)00338-X
- Cell Res, 2020 27;1-16
- J Hematol Oncol, 2020 13(1):95
- Nat Cell Biol, 2020 4
- Cell, 2019 36(2):179-193
- Cell, 2019 178(2):361-373
- Cell, 2019 178(2):302-315.e23
- Cancer Cell, 2019 36(2):179-193
- Cancer Cell, 2019 35(5):752-766
- Cancer Cell, 2019 36(1):68-83
- Cell Metab, 2019 30(1):129-142
- Nat Metab, 2019 1(11):1074-1088
- Immunity, 2018 48(4):675-687
- Cancer Discov, 2018 8(12):1598-1613
- Cancer Cell, 2017 32(4):490-505.e10
- Cell Discov, 2017 3:16048
- Cell Stem Cell, 2017 20(3):407-414.e4
- Nat Cell Biol, 2017 19(10):1226-1236
- Nat Cell Biol, 2017 19(9):1116-1129
- Nat Med, 2016 22(3):262-9
- Nature, 2016 538(7626):477-482
- Nat Microbiol, 2016 1:15034
- Blood, 2013 121(10):1850-7
- Blood, 2013 122(9):1587-98
- Blood, 2011 117(26):7145-54
- Hear Res, 2025 455:109165
- Nat Commun, 2024 15(1):1041
- Cell Rep Med, 2024 5(3):101471
- Theranostics, 2024 14(3):1224-1240
- Cell Death Differ, 2024 10.1038/s41418-024-01417-z
- Redox Biol, 2024 76:103323
- J Neuroinflammation, 2024 21(1):83
- Cell Death Dis, 2024 15(5):373
- Cell Rep, 2024 43(2):113678.
- JCI Insight, 2024 9(2)e173863
- Aging Cell, 2024 e14385.
- Elife, 2024 12RP92889
- J Transl Med, 2024 22(1):176
- Cell Death Discov, 2024 10(1):417
- Cell Death Discov, 2024 10(1):421
- Cell Death Discov, 2024 10(1):175
- Ocul Surf, 2024 32:198-210
- Cells, 2024 13(6)528
- iScience, 2024 27(1):108503
- Geroscience, 2024 46(5):4185-4202
- Sci Rep, 2024 14(1):23178
- J Alzheimers Dis, 2024 97(4):1751-1763
- PLoS One, 2024 19(1):e0295629
- Sci Adv, 2024 10(11):eadk7329
- bioRxiv, 2024 2024.02.27.582353
- bioRxiv, 2024 2024.01.08.574768
- Nat Aging, 2024 10.1038/s43587-024-00704-1
- bioRxiv, 2024 2024.05.10.593637
- Nat Commun, 2023 14(1):441
- J Clin Invest, 2023 133(16)e167651
- Cancer Res, 2023 83(1):141-157
- Haematologica, 2023 108(10):2626-2638
- Cell Death Dis, 2023 14(7):441
- Clin Cancer Res, 2023 29(16):3151-3161
- Cell Rep, 2023 42(2):112058
- Cell Rep, 2023 42(8):112925
- JCI Insight, 2023 8(18)e164216
- Elife, 2023 12e88329
- Br J Cancer, 2023 10.1038/s41416-023-02430-8
- Bioeng Transl Med, 2023 8(2):e10429
- Cell Death Discov, 2023 9(1):1
- Cells, 2023 12(3)380
- Cells, 2023 10.3390/cells12182247
- iScience, 2023 26(8):107369
- Int J Mol Sci, 2023 10.3390/ijms242115571
- Cancers (Basel), 2023 10.3390/cancers15194799
- Cancers (Basel), 2023 15(2)378
- Mol Cells, 2023 46(7):420-429
- PLoS One, 2023 18(1):e0280507
- PLoS One, 2023 18(2):e0277307
- Anticancer Res, 2023 43(5):1901-1908
- bioRxiv, 2023 2023.07.12.548696
- bioRxiv, 2023 2023.05.15.540869
- bioRxiv, 2023 10.1101/2023.10.26.564218
- bioRxiv, 2023 2023.12.22.573123
- Nat Commun, 2022 13(1):1199
- J Clin Invest, 2022 132(13)e145099
- Nat Chem Biol, 2022 10.1038/s41589-022-00996-7
- Blood Cancer J, 2022 12(3):39
- Theranostics, 2022 12(5):2427-2444
- Theranostics, 2022 12(17):7476-7490
- Proc Natl Acad Sci U S A, 2022 119(9)e2117402119
- ACS Appl Mater Interfaces, 2022 10.1021/acsami.1c22138
- J Eur Acad Dermatol Venereol, 2022 10.1111/jdv.18051
- Cell Death Dis, 2022 13(11):979
- Cell Death Dis, 2022 13(9):760
- Cell Rep, 2022 38(9):110448
- Cell Rep, 2022 40(5):111153
- JCI Insight, 2022 7(19)e159357
- JCI Insight, 2022 7(14)e158207
- Biomed Pharmacother, 2022 150:113034
- Blood Adv, 2022 bloodadvances.2022007364
- Oxid Med Cell Longev, 2022 2022:9518592
- Cells, 2022 11(24)4026
- Stem Cell Reports, 2022 17(2):259-275
- Biochem Pharmacol, 2022 200:115045
- iScience, 2022 25(11):105458
- Front Pharmacol, 2022 13:933112
- Int J Mol Sci, 2022 23(22)13751
- Front Cell Dev Biol, 2022 10:768579
- Front Endocrinol (Lausanne), 2022 13:935106
- Aging (Albany NY), 2022 14(16):6381-6414
- Cancers (Basel), 2022 14(21)5182
- Cancers (Basel), 2022 14(6)1537
- Biomedicines, 2022 10(3)638
- Pharmaceuticals (Basel), 2022 15(1)91
- Front Med (Lausanne), 2022 9:908639
- Nat Aging, 2022 2(2):115-124
- University of East Anglia, 2022
- Nat Commun, 2021 12(1):1134
- Nat Commun, 2021 12(1):1281
- Dev Cell, 2021 S1534-5807(21)00360-9
- Cancer Res, 2021 81(23):5935-5947
- Cancer Res, 2021 81(17):4603-4617
- Haematologica, 2021 10.3324/haematol.2021.278743
- Sci China Life Sci, 2021 10.1007/s11427-021-1933-7
- Cell Death Dis, 2021 12(4):406
- Cell Death Dis, 2021 12(8):741
- Cell Death Dis, 2021 12(1):54
- Cell Death Dis, 2021 12(1):121
- Cell Rep, 2021 34(11):108870
- Br J Cancer, 2021 10.1038/s41416-021-01441-7
- Cell Rep, 2021 36(1):109334
- Oncogene, 2021 10.1038/s41388-021-01910-6
- Antioxidants (Basel), 2021 10(6)956
- Cell Death Discov, 2021 7(1):275
- Mol Oncol, 2021 10.1002/1878-0261.13060
- Clin Sci (Lond), 2021 135(15):1873-1895
- Cells, 2021 10(7)1643
- NPJ Breast Cancer, 2021 7(1):60
- Mol Cancer Ther, 2021 molcanther.MCT-21-0474-A.2021
- Int J Mol Sci, 2021 22(24)13233
- Int J Mol Sci, 2021 22(8)3811
- Int J Mol Sci, 2021 22(2)E752
- Mol Cancer Res, 2021 19(4):651-666
- Cancers (Basel), 2021 13(16)4123
- Cancers (Basel), 2021 13(14)3464
- Transl Oncol, 2021 14(5):101048
- Molecules, 2021 26(7)2045
- PLoS Comput Biol, 2021 17(2):e1008630
- BMC Geriatr, 2021 21(1):225
- BMC Complement Med Ther, 2021 21(1):88
- Tissue Eng Regen Med, 2021 18(5):841-850
- Sci Transl Med, 2020 15;12(539) pii: eaax3799
- Nat Commun, 2020 11(1):752
- Nat Commun, 2020 11(1):259
- Mol Cell, 2020 7;S1097-2765(20)30269-0
- Blood Cancer J, 2020 10(6):72
- EMBO Mol Med, 2020 12(12):e12391
- Mol Syst Biol, 2020 16(2):e8664
- Cancer Lett, 2020 S0304-3835(20)30635-2
- Cell Death Dis, 2020 11(10):854
- Cell Death Dis, 2020 11(3):177
- Cell Death Dis, 2020 8;11(6):443
- Cell Rep, 2020 32(2):107897
- Cell Rep, 2020 31(13):107830
- Eur J Cancer, 2020 126:93-103
- Aging Cell, 2020 19(4):e13133
- Elife, 2020 2;9:e54954
- Breast Cancer Res, 2020 22(1):130
- Free Radic Biol Med, 2020 152:227-234
- J Med Chem, 2020 63(22):13733-13744
- Int J Radiat Oncol Biol Phys, 2020 S0360-3016(20)34731-3
- Antioxidants (Basel), 2020 9(11)E1143
- Int J Radiat Oncol Biol Phys, 2020 15;106(4):867-877
- Biomater Sci, 2020 8(8):2264-2273
- Int J Cancer, 2020 10.1002/ijc.33393
- NPJ Breast Cancer, 2020 6:30
- Cancer Sci, 2020 111(10):3793-3801
- Front Pharmacol, 2020 11:615505
- Cancers (Basel), 2020 12(9)E2551
- Mol Cancer Res, 2020 18(4):537-548
- Aging (Albany NY), 2020 12(14):14174-14188
- Aging (Albany NY), 2020 7;12(9):8221-8240
- Cancers (Basel), 2020 10;12(2) pii: E406
- Mol Cancer Res, 2020 molcanres.0586.2020
- Cancers (Basel), 2020 12(8):E2137
- Cancers (Basel), 2020 12(8):E2298
- FASEB J, 2020 10.1096/fj.201900218R
- Sci Rep, 2020 14;10(1):222
- PLoS Negl Trop Dis, 2020 14(3):e0008150
- PLoS One, 2020 15(7):e0234103
- Platelets, 2020 10.1080/09537104.2020.1724276
- Biochem Biophys Res Commun, 2020 4;526(3):612-617
- Mol Biol Rep, 2020 47(6):4849-4856
- Leuk Lymphoma, 2020 1-5
- Laryngoscope, 2020 10.1002
- Anat Cell Biol, 2020 53(4):471-480
- Trop Life Sci Res, 2020 31(3):1-13
- Mol Cell, 2019 74(1):19-31
- Nat Chem Biol, 2019 15(3):232-240
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-0775
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-1398
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-0713
- EMBO Mol Med, 2019 11(10):e10769
- Cell Death Dis, 2019 10(5):342
- Cell Chem Biol, 2019 10.1016/j.chembiol.2019.04.011
- Oncogene, 2019 38(1):47-59
- Elife, 2019 8
- Stem Cell Res Ther, 2019 10(1):86
- Cell Biosci, 2019 9:60
- Br J Pharmacol, 2019 10.1111/bph.14773
- J Med Chem, 2019 62(15):6913-6924
- Thyroid, 2019 29(4):540-548
- Cell Oncol (Dordr), 2019 42(3):287-301
- Cancer Cell Int, 2019 19:218
- Cancer Cell Int, 2019 19:222
- Int J Mol Sci, 2019 20(23)
- Transl Oncol, 2019 12(4):683-692
- J Biol Chem, 2019 294(3):875-886
- FASEB J, 2019 10.1096/fj.201900815RR
- Sci Rep, 2019 9(1):1897
- Sci Rep, 2019 9(1):5912
- Pigment Cell Melanoma Res, 2019 10.1111/pcmr.12841
- BMC Cancer, 2019 19(1):1251
- BMC Cancer, 2019 20(1):1
- Mol Pharmacol, 2019 96(4):419-429
- Photodiagnosis Photodyn Ther, 2019 10.1016/j.pdpdt.2019.08.016
- Cancer Biomark, 2019 24(1):51-59
- Prostate, 2019 79(11):1347-1359
- Sci Adv, 2019 5(7):eaau9433
- Nat Commun, 2018 9(1):215
- Neuro Oncol, 2018 20(2):203-214
- J Exp Med, 2018 215(1):319-336
- Nucleic Acids Res, 2018 46(19):10195-10215
- Nat Chem Biol, 2018 14(2):112-117
- J Allergy Clin Immunol, 2018 142(5):1647-1650.e3
- Cell Death Dis, 2018 9(10):944
- Cell Death Dis, 2018 9(7):713
- Cell Death Dis, 2018 9(2):21
- Cell Death Dis, 2018 9(9):907
- Cell Death Dis, 2018 92(10)
- Cell Death Dis, 2018 9(5):445
- Oncogene, 2018 37(22):2936-2952
- Biomed Pharmacother, 2018 107:139-145
- Stem Cell Res Ther, 2018 9(1):108
- Cell Death Discov, 2018 4:107
- Antioxidants (Basel), 2018 10.3390/antiox7110150
- Mol Oncol, 2018 12(3):287-304
- Mar Drugs, 2018 16(12)
- Oncotarget, 2018 9(28):20075-20088
- Oncotarget, 2018 9(24):16701-16717
- Sci Rep, 2018 8(1):16822
- Cell Physiol Biochem, 2018 48(3):1123-1138
- Cell Cycle, 2018 17(17):2175-2186
- Toxicol In Vitro, 2018 46:229-236
- bioRxiv, 2018 10.1101/397216
- Nat Commun, 2017 8:16078
- Nat Commun, 2017 8(1):1940
- Nat Commun, 2017 8(1):1067
- J Clin Invest, 2017 127(2):635-650
- Cancer Res, 2017 77(9):2512-2521
- Cancer Res, 2017 77(8):2018-2028
- Cancer Res, 2017 77(13):3513-3526
- Cancer Res, 2017 77(9):2476-2487
- Proc Natl Acad Sci U S A, 2017 114(2):382-387
- Cell Death Dis, 2017 8(10):e3062
- Cell Commun Signal, 2017 15(1):16
- Acta Pharmacol Sin, 2017 38(12):1632-1641
- Aging Cell, 2017 16(4):693-703
- J Cell Biol, 2017 216(11):3655-3675
- Biomed Pharmacother, 2017 95:1574-1579
- Mol Cancer Ther, 2017 16(11):2563-2571
- Mol Cancer Ther, 2017 16(10):2178-2190
- Oncotarget, 2017 8(18):29558-29573
- Oncotarget, 2017 8(49):86312-86324
- Oncotarget, 2017 8(34):57047-57057
- Int J Oncol, 2017 10.3892/ijo.2017.3914
- Viruses, 2017 9(10)
- Dis Model Mech, 2017 10(9):1109-1115
- Anticancer Drugs, 2017 28(10):1141-1149
- Tumour Biol, 2017 39(5):1010428317699120
- Nat Commun, 2016 7:11363
- Autophagy, 2016 12(7):1083-93
- Clin Cancer Res, 2016 pii: clincanres.2827.2015
- Leukemia, 2016 30(2):351-60
- Cancer Res, 2016 76(23):7001-7011
- Proc Natl Acad Sci U S A, 2016 113(6):1624-9
- Elife, 2016 10.7554/eLife.18489
- Anal Chem, 2016 88(16):8050-7
- Int J Cancer, 2016 138(2):507-14
- Oncotarget, 2016 7(50):82013-82027
- Oncotarget, 2016 7(1):845-59
- Oncotarget, 2016
- Oncotarget, 2016 7(23):34453-71
- Aging (Albany NY), 2016 8(11):2915-2926
- Cell Cycle, 2016 15(3):394-402
- Endocr Relat Cancer, 2016 23(1):35-45
- PLoS One, 2016 11(10):e0164250
- PLoS One, 2016 11(12):e0167599
- PLoS One, 2016 11(6):e0158617
- Cancer Biol Ther, 2016 17(1):27-35
- Mol Med Rep, 2016 13(1):403-11
- Biochem Biophys Res Commun, 2016 478(4):1792-7
- J Biomol Screen, 2016 21(7):680-8
- Data Brief, 2016 6:710-4
- Cell Death Differ, 2015 10.1038/cdd.2015.73
- Cell Death Dis, 2015 6:e2034
- EMBO Rep, 2015 16(5):618-27
- Breast Cancer Res, 2015 17:26
- Breast Cancer Res, 2015 17(1):533
- Int J Cancer, 2015 137(12):2959-70
- Open Biol, 2015 5(3)
- Mol Cancer Ther, 2015 14(1):298-306
- Oncotarget, 2015
- Oncotarget, 2015 6(29):27388-402
- Oncotarget, 2015 6(25):21557-71
- Oncotarget, 2015 6(17):15551-65
- Oncotarget, 2015
- Oncotarget, 2015 6(34):36456-71
- Frontiers in Oncology, 2015 4:368
- Sci Rep, 2015 5:14739
- Sci Rep, 2015 5:16406
- PLoS One, 2015 10(3):e0120913
- Ann Surg Oncol, 2015 22(9):3079-86
- PLoS One, 2015 10(1):e0116998
- Microvasc Res, 2015 101:72-81
- Oncol Lett, 2015 10(2):829-834
- J Clin Invest, 2014 124(1):117-28
- J Clin Invest, 2014 124(11):4737-52
- Proc Natl Acad Sci USA, 2014 111(41):14788-93
- Cell Death Dis, 2014 5:e1291
- Cell Death Dis, 2014 5:e1028
- Oncogene, 2014 10.1038/onc.2014.21
- Int J Cancer, 2014 136(3):688-98
- Oncotarget, 2014 5(21):10237-50
- Skelet Muscle, 2014 4(1):4
- Antimicrob Agents Chemother, 2014 10.1128/AAC.02798-13
- J Biol Chem, 2014 289(38):26481-91
- PLoS One, 2014 ;9(6):e99404
- PLoS One, 2014 9(10):e108371
- Assay Drug Dev Technol, 2014 12(9-10):514-26
- Cell Death Differ, 2013 20(11):1475-84
- Haematologica, 2013
- Cell Death Dis, 2013 4:e883
- Cell Death Dis, 2013 4:e742
- Int J Cancer, 2013 132(4):978-87
- J Neurosci, 2013 33(12):5195-207
- Neoplasia, 2013 15(5):568-78
- Cell Cycle, 2013 12(18):2960-8
- PLoS One, 2013 8(5):e64051
- Exp Dermatol, 2013 22(8):518-23
- Biochem Biophys Res Commun, 2013 434(3):695-700
- Helsinki Metropolia University, 2013 Jens Desloovere
- Cancer Res, 2012 72(12):2949-56
- Cancer Lett, 2012 339(2):288-97
- Cell Death Dis, 2012 3:e351
- Oncogene, 2012 32(37):4331-42
- J Biol Chem, 2012 287(34):28598-608
- Toxicol Sci, 2012 128(1):79-91
- Mol Biol Cell, 2012 23(12):2240-52
- Transfusion, 2012 52(10):2094-103
- Clin Cancer Res, 2011 17(12):3956-68
- Cancer Res, 2011 71(13):4518-26
- PLoS One, 2011 6(9):e24590
- PLoS One, 2011 6(8):e21980
- Biochem Biophys Res Commun, 2011 408(2):344-9
- Clin Cancer Res, 2010 16(16):4217-25
化学信息&溶解度
分子量 | 974.61 |
分子式 | C47H55ClF3N5O6S3 |
CAS号 | 923564-51-6 |
Smiles | CC1(CCC(=C(C1)CN2CCN(CC2)C3=CC=C(C=C3)C(=O)NS(=O)(=O)C4=CC(=C(C=C4)NC(CCN5CCOCC5)CSC6=CC=CC=C6)S(=O)(=O)C(F)(F)F)C7=CC=C(C=C7)Cl)C |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 100 mg/mL ( 102.6 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 102.6 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 102.6 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 100 mg/mL ( 102.6 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
40%PEG300
5%Tween80
53%ddH2O
浓度:0.8mg/ml
(0.82mM)
操作示例:以 1 mL 工作液为例,取20 μL 40mg/ml的澄清DMSO储备液加到400 μL PEG300中,混合均匀使其澄清;向上述体系中加入50 μL Tween80,混合均匀使其澄清;然后继续加入530 μL ddH2O定容至1mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。